Business
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Conduct Investor Workshop at the Mar-A-Lago Club
MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"MIAMI, Jan. 10, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., (\"HOPE\"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (\"NRx\", and collectively with HOPE, the \"Company\") (Nasdaq:NRXP), today announced it conducted an investor workshop to support planned expansion of HOPE's network of interventional psychiatry practices focused on the treatment of suicidal depression and PTSD, at the Mar-A-Lago Club in Palm Beach, FL.\n\n \n \n \n \n \n \n\n \nThe event was attended by Qualified Institutional Buyers as defined by the Securities and Exchange Commission and included Jonathan Javitt, MD, MPH, Chairman and CEO of NRx together with Dallas Sauer, Founder of Smith and Sauer, the private investment firm that recently committed to invest in both NRx and HOPE. No formal meetings were conducted with members of the incoming administration.\nKey areas of investor discussions included:\nHOPE's mission to build an international network of best-in class, EBITDA positive, interventional psychiatry clinics$25 million financing committed by Smith and Sauer (JGS Holdings LLC) to leverage anticipated bank financing projected to secure $100 million in HOPE clinic revenue stream on a pro-forma basisRecently announced progress for HOPE's initial clinic acquisitionsPotential mechanisms for follow-on non-dilutive financing to expand HOPE's network by an additional 50 clinics in 2026 and 100 clinics in 2027Plans for integration of new technologies and a CRM-based information technology and telepsychiatry umbrella to span the HOPE networkBased on the results of today's meeting, NRx has been invited to return to Mar-A-Lago for an expanded meeting during the last week of January 2025 that will include both Qualified Institutional Buyers and Accredited Investors. Individuals interested in attending are invited to contact Matthew Duffy, Co-CEO of HOPE Therapeutics.\n\"We were gratified by the enthusiastic response and inciteful questions we received from this group of sophisticated attendees and look forward to future discussions,\" said Jonathan Javitt, MD MPH, Founder, Chairman & CEO of NRx, and Co-CEO HOPE Therapeutics. \"Our mission to treat and prevent suicidality in our society in general, and our military/veteran communities in particular, clearly resonated with those who joined us this evening....